The administrarion of a small dose of nondepolarizing neuromuscular blocking agent before the injection of suxamethonium is used widely to prevent, or limit, the untoward side effects of suxamethonium. Variable success has been reported with this procedure in decreasing muscle fasciculations, postoperative muscle pain, and the frequency of cardiac arrhythmia Ferguson and Bevan, 1981; Ferres et al., 1983) . However, precurarization itself is not free from unpleasant and serious reactions, and may result in changes in pulmonary function and neuromuscular transmission (Howardy-Hansen et al., 1980; Rao and Jacobs, 1980; Engbaek and Viby-Mogensen, 1984; Engbaek et al., 1985) . Alcuronium has never been included in such studies and data with vecuronium have been published only for awake nonpremedicated volunteers. In many hospitals " precurarization " implies the injection of a fixed dose of non-depolarizing blocking drug independent of the weight of the patient (Bennets and Khalil, 1981; Ferres et al., 1983; Engbaek and Viby-Mogensen, 1984) .
The aim of this study was to compare the changes in pulmonary function caused by standard pretreatment doses of alcuronium 2 mg, pancuronium 1 mg and vecuronium 1 mg in premedicated patients immediately before surgery.
PATIENTS AND METHODS
One hundred and sixty patients (ASA grade I or II) undergoing elective surgery were studied. All were free from neuromuscular disease and had normal pulmonary function (Morris, Koski and Johnson, 1971) . Written informed consent was obtained from each patient and the study was approved by the local Ethics Committee. The patients were randomly allocated to three groups (table I): 55 patients received a standard pretreatment dose of alcuronium 2 mg (group 1), 52 patients received pancuronium 1 mg (group 2), and 53 patients vecuronium 1 mg (group 3). Pulmonary function was determined using a digital spirometer with automated BTPS correction (Spirotron, Draeger AG (Knorpp, 1975) ). The following indices were calculated from the flow-volume loops: peak expiratory flow (PEF), forced vital capacity (FVC), forced expiratory flow (FEF), forced expiratory volume at 0.5 s, 1 s, and 3 s, respectively (FEV 0 6 , FEV 13 FEV,).
The evening before the operation all patients were trained in the use of the spirometer and the resting values for the supine position were determined (measurement A). Thirty to 45 min after premedication with either droperidolfentanyl and atropine, or pethidine and atropine, the patjents were transferred to the anaesthetic induction room and placed in the supine position on an operating table. An i.v. infusion was started and the ECG continuously monitored. After registration of pulmonary function (measurement B) the pretreatment dose of neuromuscular blocking agent was injected. Two minutes later the patients were questioned about the following symptoms: heavy eyelids, blurring of vision, general discomfort, difficulty in speaking, breathing and swallowing. In addition, they were asked to lift the head and sustain this position for more than 10 s. Note was taken of any evidence of ptosis or signs of respiratory distress. Thereafter pulmonary function was measured again (measurement C). Anaesthesia was then induced with thiopentone 3-5 mg kg" 1 , and after the administration of suxamethonium 1 mg kg" 1 the trachea was inrubated.
Evidence of side effects of suxamethonium was sought by at least three persons who scanned the whole patient for muscle fasciculations and the occurrence of a flush. Simultaneously, the ECG was carefully monitored for evidence of arrhythmia. The next day the patients were asked about muscle pain and headache, as well as about discomfort during the precurarization period.
Statistical analysis
The Wilcoxon rank-sum test for paired data, the Kruskal-Wallis test and the chi-square test were used in the form supplied by the Statistical Package for Social Sciences (Nie et al., 1975) .
Significance was assigned at a level of 0.05.
RESULTS
The frequencies of suxamethonium associated side effects are listed in table II. The appearance of a flush was restricted to small areas and was transient, persisting for more than 5 min in only 4 % of patients. Changes in heart rate were also temporary and did not require any therapeutic measures. Frequent, but inde- pendent of the non-depolarizing drug in use, were fasciculations which occurred in more than 69 % of patients. The frequency of marked fasciculation and muscle movement varied from 11 % to 25 %. There was no correlation between the localization of fasciculations and muscle pain. Muscle pain, in an extent to cause spontaneous complaint, was manifested mainly in the neck and the back. There were no statistically significant differences between alcuronium, pancuronium and vecuronium in their ability to prevent any of the side effects associated with suxamethonium. However, differences between the three non-depolarizing myoneural blocking agents did become obvious with respect to the frequency with which the side effects of precurarization itself were found (table  III) .
Significantly more patients in the pancuronium and vecuronium groups had difficulty in speaking, whereas the feelings of a heavy tongue and difficulty in swallowing were most pronounced in the vecuronium group. Difficulty in breathing was reported by one patient receiving alcuronium, by two patients receiving pancuronium, and by five patients receiving vecuronium, but only the three patients in the pancuronium and alcuronium groups were unable to perform the ventilatory function test after pretreatment. Premedication influenced only PEF. This change was evident in all groups, but was too small to achieve significance in the Kruskal-Wallis test.
There were statistically significant differences between the three neuromuscular blocking agents in their effects on ventilatory function (table  IV) .
Precurarization with alcuronium and pancuronium was followed by small decreases in PEF of 6% and 11%, respectively. The reductions in FVC amounted to 4% and 9%, those for FEV! to 5% and 9%, respectively. Significant changes were seen only when vecuronium was used as the fixed dose precurarization agent. PEF was reduced by 24%, FVC by 19% and FEV X by 19% ( fig. 1 ).
DISCUSSION
Fixed dose precurarization with the three nondepolarizing neuromuscular blocking agents was successful in preventing severe suxamethoniumassociated side effects, although a number of lesser manifestations still occurred. The pretreatment itself, however, resulted in physical signs and symptoms of partial neuromuscular blockade, which produced a general feeling of discomfort in the patient and eventually impaired pulmonary function. Of the ventilatory variables measured, PEF was reduced by 6 % with alcuronium, 11 % with pancuronium and 24% with vecuronium. The reductions in FVC by alcuronium, pancuronium and vecuronium were 4%, 9% and 19%, respectively, and those for FEVj were 5 %, 9 % and 19%, respectively. Although the deterioration in ventilatory function was most obvious with vecuronium, two patients in the pancuronium group and one in the alcuronium group were unable to perform the pulmonary function tests at all following precurarization.
Premedication was included deliberately in the design of this study, in order to follow the usual local clinical routine, especially since most previous studies have been undertaken in healthy, unpremedicated volunteers. Howardy-Hansen and colleagues (1980) speculated that the frequency of general discomfort may be reduced by premedication. This view was supported by our findings, since the frequency of general discomfort was 6%, which was in contrast to their report of general discomfort in 80% of the patients receiving pancuronium 0.015 mg kg" 1 , which is a dose similar to the standard dose, used in the present study, of 1 mg in a 70-kg person. The expectation put forward by Rao and Jacobs (1980) , that ventilatory responses to precurarization may be aggravated by premedication, was not substantiated.
Pulmonary function was measured by us routinely 2 min after the injection of the nondepolarizing myoneural blocker. In view of the recent data by Agoston, Ket and Rashkovsky (1985) , that the onset time of pancuronium and vecuronium is five times shorter than that of alcuronium (2 min v. 10 min), the time delay of 2 min as chosen by us may have been too short to permit the full development of partial curarization when alcuronium was used-although efficacy in preventing suxamethonium side effects was established.
Although there exists a tendency to rank the equivalent doses of the three drugs as 3:1:0.75 for alcuronium, pancuronium and vecuronium, pretreatment doses of pancuronium 1 mg or alcuronium 2 mg, as used in the present study, are the most common clinical regimens (Ferres et al., 1983; Engbaek and Viby-Mogensen, 1984) . Routine administration of a fixed dose of alcuronium 2 mg or pancuronium 1 mg seems to be a safe and clinically effective procedure. Vecuronium should be used in a dose of about 0.5-0.75 mg if preference is not for an exact dose per weight method and 0.01 mg kg" 1 used. Nevertheless, patients should always be informed about possible side effects and, in view of the striking variation in individual sensitivity, it is important that the patient's reactions be carefully monitored and ventilatory support instituted immediately if needed.
